BARD1
- Known as:
- BARD1
- Catalog number:
- 002411A
- Product Quantity:
- 250ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- BARD1
Related genes to: BARD1
- Gene:
- BARD1 NIH gene
- Name:
- BRCA1 associated RING domain 1
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 2q35
- Locus Type:
- gene with protein product
- Date approved:
- 1998-08-05
- Date modifiied:
- 2019-04-23
Related products to: BARD1
Related articles to: BARD1
- Hereditary factors account for a significant lifetime risk of breast cancer. Approximately 20% is attributable to pathogenic variants in the highly penetrant BRCA1/2 of the homologous recombination repair (HRR) pathway. Other HRR pathway genes (ATM, CHEK2, BARD1, TP53) are also linked to breast cancer susceptibility; however, the contribution of these genes remains underexplored in Pakistani populations. - Source: PubMed
Publication date: 2026/09/22
Saleem HumairaNasir MahrukhKhan SamraIrfan MuhammadShakeel MuhammadSaleem LubnaShafiq-Ur-Rehman Khan Ishtiaq Ahmad - Understanding what drives the choice between homologous recombination (HR) and non-homologous end joining (NHEJ) as the DNA double-strand break (DSB) repair pathway can help to elucidate mechanisms of genome repair and acquired drug resistance in cancer cells. This choice is intimately linked with a highly regulated process of DNA end resection, mediated by several nuclease entities. Concerted efforts by many laboratories have identified several factors involved in DNA end resection, but we are only beginning to appreciate the mechanisms that underpin DSB repair pathway choice. In this Review, we highlight how DSB repair factors, DSB repair regulators and chromatin modifications determine whether HR or NHEJ is engaged as the repair pathway, with a focus on the antagonistic roles of the tumour suppressor complex BRCA1-BARD1 and the 53BP1 axis in repair pathway choice. How RNA-DNA hybrids affect HR execution and how they are processed by helicases and HR factors is also discussed. Moreover, we describe how dysfunction in repair pathway choice affects tumorigenesis and drives chemotherapeutic resistance. - Source: PubMed
Publication date: 2026/09/18
Swift Michelle LRogers Cody MKaur HardeepChowdhury DipanjanSung Patrick - This study aims to investigate the mutational spectrum of and genes in a cohort of breast cancer (BC) patients from southern Tunisia, and to evaluate their clinical and prognostic significance. Additionally, this study explores the contribution of other cancer predisposition genes and the prevalence of variants of uncertain significance (VUS). - Source: PubMed
Publication date: 2026/08/29
Ammous-Boukhris NihelAbdelmaksoud-Dammak RaniaBen Kridis WalaBen-Ayed-Guerfali DorraGuidara SouhirFeki AmeniKamoun HassenKhanfir AfefDaoud JamelLizard Gérard-HubertGargouri AliMokdad-Gargouri Raja - Breast cancer remains highly prevalent, where the lifetime risk before age 75 is one in 13. However, known genetic factors were only identified in 14.7% of cases in our Hong Kong Hereditary Breast Cancer Family Registry. Our current local policy for genetic testing does not cover the detection of beyond . Here we highlight the clinical value of extending testing to beyond susceptibility genes for improved prevention, diagnosis, and management. We recruited 6597 hereditary breast and ovarian cancer (HBOC) patients from our registry based on family history and clinical criteria. Germline mutations were identified by multi-gene sequencing analysis using next-generation sequencing (NGS). Clinical-pathological characteristics of and beyond carriers were compared and the real-world management and surveillance services adopted in Hong Kong were highlighted. In this multi-gene hereditary cancer cohort, germline mutations were identified in 10.9% of cases for and 3.5% for beyond susceptibility genes. These beyond mutations constitute a considerable proportion of actionable hereditary risk. Notably, emerged as the most prevalent non- gene, followed by , , and . New cancers or recurrences were detected during their surveillance; the overall pick up rates were 8.3% (), 29.4% (), 33.3% () and 5.6% (). This study provides the first comprehensive characterization of the beyond germline landscape in a Hong Kong hereditary cancer cohort and highlights the current need for implementing multi-gene sequencing analysis and surveillance services for HBOC patients, establishing the predominant non- drivers and providing a robust empirical basis for expanding public genetic screening frameworks. - Source: PubMed
Publication date: 2026/08/24
Kwong AvaHo Cecilia Y STey Sze KeongAu Chun HangMa Edmond S K - Ovarian cancer is one of the leading causes of death from gynecological cancer worldwide. Genetic mutations in genes involved in key cellular functions such as BRCA1/2 play a central role in tumorigenesis and have major implications for targeted therapeutic strategies, especially the use of poly (ADP-ribose) polymerase (PARP) inhibitors. - Source: PubMed
Ammous-Boukhris NihelAbdelmaksoud-Dammak RaniaFeki AmeniKhemiri SouhirCharfi SlimSallemi-Boudawara TahiaDaoud JamelKhanfir AfefGargouri Raja Mokdad